X-Chem and Kymera Expand Existing Partnership

Author's Avatar
Jan 31, 2023

X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera+Therapeutics%2C+Inc. (NASDAQ: KYMR). With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based screening services to Kymera — with X-Chem applying its world-leading DEL platform to support Kymera’s discovery of first- and best-in-class protein degraders. The expanded partnership comprises 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration.